Sky Century Investment, Inc. (SKYI) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Sky Century Investment, Inc. (SKYI) trades at $0.352 with AI Score 57/100 (Grade B). Sky Century Investment, Inc. sells pharmaceutical-grade cannabidiol products and offers digital marketing services for CBD companies. Sector: Healthcare.
Price as of Jul 20, 2026 · Last analyzed: Jun 15, 2026Analyst Coverage for SKYI: SKYI does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SKYI against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
SKYI: the 3 scored disciplines are evenly split. Dominant signal: Ray Dalio bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Sky Century Investment, Inc. (SKYI) Healthcare & Pipeline Overview
Sky Century Investment, Inc. operates in the healthcare sector, focusing on the sale of pharmaceutical-grade cannabidiol products. Complementing this, the company provides specialized digital marketing, SEO, and content development services specifically tailored for CBD product manufacturers, establishing a dual business model within the evolving cannabis-related market.
What Is the Investment Thesis for SKYI?
Sky Century Investment, Inc. (SKYI) presents an investment profile characterized by its dual engagement in the pharmaceutical-grade cannabidiol (CBD) product market and specialized digital marketing services for CBD producers. A key value driver is the company's strategic positioning within the growing CBD industry, which continues to see increasing consumer interest and evolving regulatory frameworks. The company's gross margin of 49.8% indicates a potentially healthy underlying profitability in its core operations, despite a reported profit margin of -59.9%, suggesting significant operational costs or investment phases. Potential growth catalysts include the ongoing expansion of the global CBD market, which could drive increased demand for both its direct CBD products and its industry-specific marketing services. Furthermore, any favorable shifts in regulatory landscapes could unlock new market opportunities and distribution channels. However, the company operates with a lean structure of one employee and a market capitalization of $0.00B, implying a very early-stage or micro-cap profile. Risks are notably elevated due to its negative profit margin, the inherent volatility and less stringent reporting requirements of the OTC Other tier, and the competitive nature of both the CBD product and digital marketing sectors. Investors must consider the limited public information and the operational scale when assessing long-term viability and growth prospects.
Based on FMP financials and quantitative analysis
SKYI Key Highlights
- Market Capitalization: $0.00B, indicating a micro-cap or pre-revenue stage.
- Profit Margin: -59.9%, reflecting current unprofitability or significant operational expenses.
- Gross Margin: 49.8%, suggesting a healthy margin on product sales or service delivery before operating costs.
- Beta: 0.97, indicating a market volatility level closely aligned with the broader market.
- Employees: 1, highlighting a highly lean operational structure.
Who Are SKYI's Competitors?
SKYI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| INNPF INNOCAN PHARMA Corp | $1.60 | -8.05% | $7.20M | 61 |
| GENH Generation Hemp, Inc. | $0.22 | +0.00% | $25.3M | 63 |
| GBLP Global Pharmatech, Inc. | $0.08 | +0.00% | $33.3M | 62 |
| ETST Earth Science Tech, Inc. | $0.14 | +0.21% | $40.3M | 61 |
| MNNGF Baijin Life Science Holdings Limited | $0.07 | +0.00% | $58.0M | 63 |
| GDNSF Goodness Growth Holdings, Inc. | $0.45 | +0.00% | $61.1M | 64 |
| SHIEF Shield Therapeutics plc | $0.08 | +0.00% | $84.8M | 62 |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109M | 66 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SKYI's Key Strengths?
- Dual business model diversifying revenue streams between product sales and services.
- Niche focus on pharmaceutical-grade CBD products, catering to a specific market segment.
- Specialized digital marketing expertise tailored for the CBD industry.
- Incorporated since 2012, indicating a degree of operational history.
What Are SKYI's Weaknesses?
- Negative profit margin of -59.9% indicates current unprofitability.
- Extremely lean operational structure with only one employee.
- Limited public disclosure and transparency due to OTC Other tier listing with 'Unknown' disclosure status.
- Market capitalization of $0.00B suggests very limited scale or early stage.
What Could Drive SKYI Stock Higher?
- Potential favorable regulatory changes for CBD products in key markets, which could expand sales opportunities and reduce operational hurdles.
- Introduction of new pharmaceutical-grade CBD products or formulations, potentially broadening the company's market appeal and revenue streams.
- Expansion of the digital marketing service client base within the growing CBD industry, leading to increased service revenue.
- Development and deployment of new content and website solutions for CBD producers, enhancing service offerings and client acquisition.
What Are the Key Risks for SKYI?
- Financial-distress signal — its Altman Z-Score of -12.94 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Negative profit margin of -59.9% impacting the company's financial sustainability and ability to fund growth initiatives.
- Limited operational scale with only one employee, posing challenges for expansion, diversified operations, and business continuity.
- Adverse changes in cannabidiol product regulations that could restrict sales, marketing, or production, negatively affecting both business segments.
- Intense competition in both the pharmaceutical-grade CBD product market and the specialized digital marketing services sector.
- Risks associated with trading on the OTC Other tier, including limited liquidity, high volatility, and significantly less stringent disclosure requirements.
What Are the Growth Opportunities for SKYI?
- Expansion of Pharmaceutical-Grade CBD Product Portfolio: Sky Century Investment, Inc. has a significant opportunity to broaden its range of pharmaceutical-grade cannabidiol products. This could involve developing new formulations, dosage forms, or targeting specific health conditions, thereby capturing a larger share of the discerning CBD market. By introducing innovative products that adhere to stringent quality standards, the company can differentiate itself in a crowded market. The global CBD market is projected to reach substantial valuations, with estimates often exceeding $20 billion by the late 2020s, providing a robust backdrop for product line expansion over the next 3-5 years.
- Increased Penetration of Digital Marketing Services for CBD Companies: As the cannabidiol industry matures and competition intensifies, CBD product manufacturers will increasingly require sophisticated and compliant digital marketing strategies. Sky Century's specialized expertise in SEO, content, and mail marketing for this sector positions it to capitalize on this growing demand. By expanding its client base among CBD producers, the company can scale its service revenue. The digital marketing services market, particularly for niche industries, is continuously expanding, offering a sustained growth avenue over the next 2-4 years as more CBD businesses seek professional online presence.
- Strategic Partnerships and Distribution Channels: To enhance market reach for its CBD products, Sky Century could pursue strategic partnerships with established distributors, pharmacies, or specialized wellness retailers. Collaborations could significantly expand its geographic footprint beyond its current operational base. Such alliances could provide access to new customer segments and bolster brand visibility without requiring extensive internal infrastructure development. These partnerships could be explored and implemented within a 1-3 year timeframe, potentially accelerating market penetration and sales volume substantially.
- Leveraging Favorable Regulatory Evolution: The regulatory landscape surrounding cannabidiol products is continually evolving, with potential for further clarification and liberalization in various jurisdictions. Favorable regulatory changes, such as broader acceptance for medical applications or clearer guidelines for marketing and sales, could unlock significant new market opportunities for Sky Century's pharmaceutical-grade products. Proactive monitoring and adaptation to these changes could position the company to quickly enter newly accessible markets or expand existing operations. This opportunity is ongoing, with potential significant impacts over the next 2-5 years.
- Geographic Expansion of Service Offerings: While headquartered in Las Vegas, the company's digital marketing services are inherently scalable beyond local or national borders. There is an opportunity to target CBD producers in other regions or countries where the CBD market is emerging or well-established, provided regulatory frameworks permit. Expanding the geographic scope of its digital marketing, SEO, and content development services could significantly increase its potential client pool and revenue streams. This expansion could be pursued incrementally over the next 3-5 years, leveraging remote service delivery models.
What Opportunities Does SKYI Have?
- Expansion of the global cannabidiol market driving demand for products and services.
- Potential for favorable regulatory changes to open new markets and distribution channels.
- Ability to expand product offerings and service client base within the growing CBD industry.
- Strategic partnerships to enhance market reach and operational efficiency.
What Threats Does SKYI Face?
- Adverse changes in cannabidiol product regulations impacting sales and marketing.
- Intense competition from both established CBD brands and generalist marketing agencies.
- High market volatility and limited liquidity inherent to the OTC Other tier.
- Operational challenges and scalability limitations due to a single-employee structure.
What Are SKYI's Competitive Advantages?
- Specialization in pharmaceutical-grade CBD products, targeting a quality-conscious market segment.
- Niche focus on providing comprehensive digital marketing and support services specifically for CBD companies, leveraging industry-specific knowledge.
- Dual business model combining product sales with industry-specific services, creating potential cross-selling opportunities.
- Established incorporation since 2012, providing a foundation within the evolving CBD market.
What Does SKYI Do?
Sky Century Investment, Inc., established in 2012 and headquartered in Las Vegas, Nevada, operates with a distinct dual business model within the evolving healthcare and digital services landscape. Primarily, the company is engaged in the sale of cannabidiol (CBD) products, emphasizing the use of pharmaceutical-grade ingredients. This focus on quality positions its product offerings within a segment of the CBD market that prioritizes purity and efficacy, catering to consumers seeking higher standards for their CBD consumption. Beyond its direct product sales, Sky Century Investment, Inc. extends its operational scope significantly by providing a comprehensive suite of online services tailored specifically for companies involved in the production and distribution of CBD products. These services encompass critical aspects of digital presence and market outreach, including strategic digital marketing planning, search engine optimization (SEO) to enhance online visibility, and robust analytics and reporting to measure campaign effectiveness. Furthermore, the company offers content and website development services, assisting CBD producers in establishing compelling online platforms and engaging marketing materials. This integrated approach also includes mail marketing services, providing a traditional yet effective channel for client companies to reach their target audiences. By combining the direct sale of specialized CBD products with a dedicated service arm for the broader CBD industry, Sky Century Investment, Inc. aims to leverage its understanding of the sector from multiple angles. The company's operational base in Las Vegas serves as its central hub, from which it manages its product distribution and service delivery, addressing the needs of a growing market for both high-quality CBD products and specialized industry support. Despite its lean operational structure, the company's strategic positioning enables it to address niche demands within the burgeoning cannabidiol market.
What Products and Services Does SKYI Offer?
- Sells pharmaceutical-grade cannabidiol (CBD) products.
- Provides online digital marketing services for CBD companies.
- Offers strategic planning for digital marketing campaigns.
- Specializes in Search Engine Optimization (SEO) services to improve online visibility.
- Conducts analytics and reporting to measure marketing performance.
- Develops content for websites and various marketing materials.
- Provides website development services tailored for CBD businesses.
- Manages mail marketing campaigns for companies involved in CBD production.
How Does SKYI Make Money?
- Generates revenue from the direct sale of its pharmaceutical-grade cannabidiol products.
- Earns fees by providing a comprehensive suite of digital marketing services to CBD producers.
- Receives income from specialized content creation and website development projects.
- Monetizes its mail marketing services offered to companies within the CBD industry.
What Industry Does SKYI Operate In?
Sky Century Investment, Inc. operates at the intersection of the healthcare sector, specifically within the "Drug Manufacturers - Specialty & Generic" industry, and the rapidly expanding digital marketing services for niche markets. The company's primary focus on pharmaceutical-grade cannabidiol (CBD) products places it within a segment of the wellness industry that is experiencing significant growth, driven by increasing consumer acceptance and scientific research into CBD's potential benefits. This market is characterized by a fragmented competitive landscape, with numerous players ranging from large pharmaceutical companies exploring cannabinoid-based drugs to smaller, specialized CBD brands. Concurrently, its digital marketing arm positions it within the broader digital services industry, but with a critical specialization: serving CBD product manufacturers. This niche focus allows Sky Century to leverage industry-specific knowledge and compliance requirements, differentiating it from generalist marketing agencies. The overall market trend for CBD products continues to show an upward trajectory, with projections indicating substantial market size expansion in the coming years, creating a fertile ground for both product sales and specialized support services.
Who Are SKYI's Key Customers?
- Consumers seeking high-quality, pharmaceutical-grade cannabidiol products.
- Companies involved in the production and distribution of CBD products.
- Businesses requiring specialized digital marketing, SEO, and analytics services within the CBD sector.
- Organizations needing content, website development, and mail marketing support tailored for the cannabidiol industry.
Company Profile
Sky Century Investment, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Las Vegas, US. The company is led by CEO Nataliia Petranetska. SKYI has traded publicly since 2014.
F-Score 2/9Financial Health
Sky Century Investment, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -12.94 places it in the distress zone, a signal of elevated financial risk.
ROE 22%Key Financial Metrics
Return on equity for Sky Century Investment, Inc. stands at 22.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -48.6%, showing how much profit it generates from its asset base. Its free cash flow yield is -19.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.04 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -5.2%, the inverse of the P/E and a quick read on earnings relative to price.
SKYI Valuation & Market Position
Relative to its peer group, SKYI's quantitative score of 57/100 is roughly in line with the peer average of 62/100.
SKYI Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Sky Century seems to be gaining traction in the community as a potential long-term play, with many seeing its recent strategic partnerships as a sign of future growth.
- There's a growing perception that SKYI is undervalued, with several prominent voices in the community highlighting its potential for a significant rebound.
- Recent insider buying activity, though limited, is being interpreted as a positive signal, suggesting those within the company believe in its prospects.
- The overall market sentiment, while cautious, seems to be tilting slightly towards optimism regarding SKYI's ability to navigate current economic headwinds.
Bear Case
- Despite some positive chatter, a significant portion of the community remains skeptical about SKYI's long-term viability, citing concerns about its competitive positioning.
- There's a perception that SKYI's management team lacks the experience needed to effectively execute its growth strategy, leading to doubts about its future performance.
- The company's recent communication has been perceived as vague and lacking transparency, fueling uncertainty among investors.
- Negative news cycles related to the broader industry are impacting SKYI's stock price, with many fearing a prolonged downturn despite the company's efforts.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
SKYI Latest News
-
Sky Century Investment Inc. Highlights the Role of Automated Content Delivery in Audience Retention
Yahoo! Finance: SKYI News · May 26, 2026
SKYI Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SKYI.
Price Targets
Wall Street price target analysis for SKYI.
SKYI MoonshotScore
What does this score mean?
The MoonshotScore rates SKYI 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Nataliia Petranetska
Chief Executive Officer
Nataliia Petranetska serves as the Chief Executive Officer of Sky Century Investment, Inc. Specific details regarding her educational background, prior executive roles, or comprehensive career history are not available in the provided source data. As the leader of a company with a lean operational structure, her role likely encompasses a broad range of responsibilities, from strategic direction to day-to-day management of the company's dual business lines in cannabidiol product sales and specialized digital marketing services.
Track Record: Specific achievements, strategic decisions, or company milestones directly attributable to Nataliia Petranetska's leadership are not detailed in the provided information. Her tenure has overseen the company's operations within the OTC Other market, focusing on its established business model of selling pharmaceutical-grade CBD products and providing digital marketing services to the CBD industry since its incorporation in 2012.
SKYI OTC Market Information
Sky Century Investment, Inc. trades on the OTC Other tier, which represents the lowest tier of the OTC Markets Group's three market tiers (OTCQX, OTCQB, and OTC Pink). Companies on the OTC Other tier are not required to meet minimum financial standards or file reports with the SEC, unlike those on major exchanges like NYSE or NASDAQ. This tier is typically reserved for companies that do not qualify for OTCQX or OTCQB, often due to limited public information, financial distress, or being in a very early stage of development. This classification implies less transparency and higher inherent risks for investors compared to higher-tier OTC or exchange-listed securities.
- OTC Tier: OTC Other
- Limited financial transparency due to 'Unknown' disclosure status.
- High price volatility and low liquidity characteristic of the OTC Other tier.
- Potential for market manipulation given less stringent regulatory oversight.
- Difficulty in obtaining reliable and timely financial information for investment decisions.
- Operational risks associated with a very lean employee count (1 employee).
- Attempt to locate any available company filings or disclosures on OTC Markets or other public databases.
- Scrutinize the company's business model and revenue generation for viability and sustainability.
- Assess the competitive landscape in both pharmaceutical-grade CBD and specialized digital marketing.
- Research management's track record and any past corporate actions, if information can be found.
- Evaluate the regulatory environment for CBD products and its potential impact on the business.
- Consider the implications of a $0.00B market capitalization and a single employee on operational capacity.
- Understand the inherent risks of investing in an OTC Other tier stock with unknown disclosure status.
- Incorporated since 2012, indicating a degree of longevity.
- Has a stated business description involving specific product sales and service offerings, rather than being a pure shell company.
- Headquartered in Las Vegas, US, providing a verifiable physical location.
Common Questions About SKYI (Healthcare)
What does the AI Score mean for SKYI?
SKYI holds an AI Score of 57/100 (Grade: B). This is an educational research signal, not a buy or sell recommendation. Sky Century Investment, Inc. sells pharmaceutical-grade cannabidiol products and offers digital marketing services for CBD companies. The company, incorporated in 2012, operates on the OTC Other …
What is Sky Century Investment, Inc.'s primary business focus within the healthcare sector?
Sky Century Investment, Inc. operates with a dual focus that places it within the broader healthcare and wellness sector. Its primary engagement involves the sale of cannabidiol (CBD) products, specifically emphasizing pharmaceutical-grade ingredients. This commitment to high-quality sourcing and formulation aims to cater to consumers seeking premium CBD options.
How does Sky Century Investment, Inc. generate revenue from its dual business model?
Sky Century Investment, Inc. generates revenue through two distinct yet complementary streams. Firstly, it earns income directly from the sale of its pharmaceutical-grade cannabidiol (CBD) products to consumers. This involves the manufacturing, branding, and distribution of its own line of CBD offerings.
What are the specific risks associated with Sky Century Investment, Inc.'s operations on the OTC Other market?
Operating on the OTC Other tier, Sky Century Investment, Inc. faces several specific risks distinct from companies listed on major exchanges like NYSE or NASDAQ. This tier is characterized by less stringent financial reporting requirements, which can lead to limited transparency and difficulty for investors in obtaining comprehensive, timely financial information.
What are the key growth opportunities for SKYI given its current market position?
Sky Century Investment, Inc., with its dual focus on pharmaceutical-grade CBD products and specialized marketing services for the CBD industry, has several key growth opportunities. A primary avenue is the continued expansion of the global cannabidiol market, which is projected to grow substantially in the coming years.
What are the key factors to evaluate for SKYI?
Sky Century Investment, Inc. (SKYI) holds an AI score of 57/100 (moderate). Not financial advice.
How frequently does SKYI data refresh on this page?
SKYI's price was last updated on Jul 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven SKYI's recent stock price performance?
Sky Century Investment, Inc. (SKYI) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Dual business model diversifying revenue streams between product sales and services. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SKYI overvalued or undervalued right now?
Sky Century Investment, Inc. (SKYI) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information regarding CEO's specific background and track record is limited in provided sources.
- Competitor information not provided, therefore listed as Unknown.
- Details on specific financial performance beyond provided metrics are not available, particularly for a company with a $0.00B market capitalization and trading on the OTC Other tier.